The chief executive officer of a Canadian cannabis distributor told jurors at the US criminal trial of Citron Research founder Andrew Left he was stunned when the prominent short-seller issued a report saying the company was overvalued, prompting shares to plunge. Cronos Group Inc. CEO Mike Gorenstein was the first witness Tuesday in the US government’s case against Left, who is accused of mislead...
The chief executive officer of a Canadian cannabis distributor told jurors at the US criminal trial of Citron Research founder Andrew Left he was stunned when the prominent short-seller issued a report saying the company was overvalued, prompting shares to plunge. Cronos Group Inc. CEO Mike Gorenstein was the first witness Tuesday in the US government’s case against Left, who is accused of misleading investors by making quick trades after issuing his investment recommendations. Gorenstein said Left’s report in August 2018 alleged Cronos was misleading investors about its distribution commitments. The CEO said the company had actually disclosed supply agreements, which weren’t a guarantee of sales. “I never really understood the report,” Gorenstein testified in Los Angeles federal court. “It didn’t make much sense.” He said Left never reached out to the company to verify any of his claims. The trial, which is expected to last about three weeks, is putting a spotlight on the short selling industry. Left is one of the most prominent players and is accused of using explosive social-media posts about dozens of companies to illegally move their stock and make a quick profit. He denies wrongdoing. Read More: Short Seller Andrew Left to Face Jury Over Alleged Manipulation During his opening statement Tuesday, prosecutor Andrew Roach told jurors that Left had become famous and influential with a “pump-and-dump, short-and-distort scheme” that earned him $20 million over the years. Defense lawyer Adam Fee argued in his opening statement that Left had earned a reputation over 25 years as a short-seller and trader by publicly disclosing his opinions about companies — something investors had valued because they made money acting on his recommendations. Gorenstein said Left had mischaracterized statements Cronos had made to investors in 2018. Prosecutors played a video clip of Left speaking on CNBC after his report on the company, noting that he claimed he was still short and expe...
咨询公司Benchmark Mineral Intelligence(BMI)周三公布的数据显示,随着汽油价格高企持续促使消费者远离燃油车,4月全球电动汽车需求连续第二个月增长。BMI表示,4月份纯电动汽车和插电式混合动力汽车的新车注册量(可视为销量指标)同比增长6%,达到160万辆,不过较3月创下的月度纪录高位下降了9%。BMI在声明中表示:“需求继续受到政策激励、汽油价格上涨以及中国制造商影响...
咨询公司Benchmark Mineral Intelligence(BMI)周三公布的数据显示,随着汽油价格高企持续促使消费者远离燃油车,4月全球电动汽车需求连续第二个月增长。BMI表示,4月份纯电动汽车和插电式混合动力汽车的新车注册量(可视为销量指标)同比增长6%,达到160万辆,不过较3月创下的月度纪录高位下降了9%。BMI在声明中表示:“需求继续受到政策激励、汽油价格上涨以及中国制造商影响力提升等因素支撑。”BMI数据显示,尽管欧盟征收关税,中国品牌在欧洲市场的份额仍在提升:2026年前四个月,欧洲售出的电动汽车和插电式混合动力车中,22%产自中国,高于上年同期的19%。 责任编辑:王永生
[The content of this article has been produced by our advertising partner.] A group of Grade 8 students from Canadian International School of Hong Kong (CDNIS) has made waves on the global innovation stage, returning from the Conrad Challenge Global Innovation Summit in Houston with multiple top honours. The team captured the coveted Innovation Summit Power Pitch Award and the Equinor Searching fo...
[The content of this article has been produced by our advertising partner.] A group of Grade 8 students from Canadian International School of Hong Kong (CDNIS) has made waves on the global innovation stage, returning from the Conrad Challenge Global Innovation Summit in Houston with multiple top honours. The team captured the coveted Innovation Summit Power Pitch Award and the Equinor Searching for Better Award – achievements that also earned them a sponsored educational trip to Boston,...
(RTTNews) - The Taiwan stock market has finished higher in two straight sessions, advancing almost 300 points or 0.7 percent along the way. The Taiwan Stock Exchange now sits just beneath the 41,900-point plateau although the rally may stall on Wednesday.
(RTTNews) - The Taiwan stock market has finished higher in two straight sessions, advancing almost 300 points or 0.7 percent along the way. The Taiwan Stock Exchange now sits just beneath the 41,900-point plateau although the rally may stall on Wednesday.
Earnings Call Insights: OptimizeRx Corporation (OPRX) Q1 2026 Management View "We delivered a solid start to the year, which exceeded consensus estimates on the top and bottom line," said (CEO & Director Stephen Silvestro), while also flagging "ongoing softness in our contracted revenue base relative to prior year levels" tied to "short to intermediate-term disruption from last year's most favored...
Earnings Call Insights: OptimizeRx Corporation (OPRX) Q1 2026 Management View "We delivered a solid start to the year, which exceeded consensus estimates on the top and bottom line," said (CEO & Director Stephen Silvestro), while also flagging "ongoing softness in our contracted revenue base relative to prior year levels" tied to "short to intermediate-term disruption from last year's most favored nation pricing dynamics and other macroeconomic factors" that are driving "more cautious budget allocations, contract durations and in some cases, the delaying of campaign timing and scope." (CEO Silvestro) highlighted product adoption and mix shift, saying "Our AI-enabled DAAP solution grew 60% in the first quarter" and "our DAAP subscription revenue also grew by 45%," adding, "This transition is an important step in improving revenue visibility and building a more durable and predictable financial model over time." (CEO Silvestro) detailed cost actions and margin expectations: "We've taken steps to align our cost structure with the current environment" and said the initiatives "are expected to reduce cash operating expenses by approximately $3 million on an annualized basis, including savings of approximately $1 million in 2026 for an in-year benefit, excluding any severance-related impacts," while adding, "we now expect full year gross margin to be in the high 60% range." (CEO Silvestro) emphasized a platform distribution change, stating, "We are now enabling demand-side platforms that control more than 80% of digital promotional dollars to connect directly into OptimizeRx proprietary EHR network," and added that programmatic access "effectively position[s] OptimizeRx as a supply-side platform" and could increase utilization versus today, where "we are utilizing less than 10% of our available inventory across the network through traditional HCP marketing initiatives." "First quarter 2026 revenue was $19.8 million, a decrease of 10% from the $21.9 million we recognized d...